These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 24326404)

  • 1. Selective detection of complementarity-determining regions of monoclonal antibody by limiting protease access to the substrate: nano-surface and molecular-orientation limited proteolysis.
    Iwamoto N; Shimada T; Umino Y; Aoki C; Aoki Y; Sato TA; Hamada A; Nakagama H
    Analyst; 2014 Feb; 139(3):576-80. PubMed ID: 24326404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validated LC-MS/MS analysis of immune checkpoint inhibitor Nivolumab in human plasma using a Fab peptide-selective quantitation method: nano-surface and molecular-orientation limited (nSMOL) proteolysis.
    Iwamoto N; Shimada T; Terakado H; Hamada A
    J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Jun; 1023-1024():9-16. PubMed ID: 27155936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validated LC/MS Bioanalysis of Rituximab CDR Peptides Using Nano-surface and Molecular-Orientation Limited (nSMOL) Proteolysis.
    Iwamoto N; Takanashi M; Hamada A; Shimada T
    Biol Pharm Bull; 2016 Jul; 39(7):1187-94. PubMed ID: 27150271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of nano-surface and molecular-orientation limited proteolysis to LC-MS bioanalysis of cetuximab.
    Iwamoto N; Takanashi M; Umino Y; Aoki C; Hamada A; Shimada T
    Bioanalysis; 2016 May; 8(10):1009-20. PubMed ID: 26972866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulated LC-MS/MS bioanalysis technology for therapeutic antibodies and Fc-fusion proteins using structure-indicated approach.
    Iwamoto N; Shimada T
    Drug Metab Pharmacokinet; 2019 Feb; 34(1):19-24. PubMed ID: 30392772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fully validated LCMS bioanalysis of Bevacizumab in human plasma using nano-surface and molecular-orientation limited (nSMOL) proteolysis.
    Iwamoto N; Umino Y; Aoki C; Yamane N; Hamada A; Shimada T
    Drug Metab Pharmacokinet; 2016 Feb; 31(1):46-50. PubMed ID: 26830079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-Indicated LC-MS/MS Bioanalysis of Therapeutic Antibodies.
    Iwamoto N; Shimada T
    Methods Mol Biol; 2022; 2313():187-205. PubMed ID: 34478139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acceleration of nano-surface and molecular-orientation limited (nSMOL) proteolysis with acidified reduction pretreatment for quantification of Tocilizumab.
    Iwamoto N; Yonezawa A; Matsubara K; Shimada T
    J Pharm Biomed Anal; 2019 Feb; 164():467-474. PubMed ID: 30447535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody drug quantitation in coexistence with anti-drug antibodies on nSMOL bioanalysis.
    Iwamoto N; Hamada A; Shimada T
    Anal Biochem; 2018 Jan; 540-541():30-37. PubMed ID: 29128290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Humanization of an anti-CD34 monoclonal antibody by complementarity-determining region grafting based on computer-assisted molecular modelling.
    Hou S; Li B; Wang L; Qian W; Zhang D; Hong X; Wang H; Guo Y
    J Biochem; 2008 Jul; 144(1):115-20. PubMed ID: 18424812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction of anti-HIV type 1 antibody 2F5 with phospholipid bilayers and its relevance for the mechanism of virus neutralization.
    Maeso R; Huarte N; Julien JP; Kunert R; Pai EF; Nieva JL
    AIDS Res Hum Retroviruses; 2011 Aug; 27(8):863-76. PubMed ID: 21142698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isomerization in the CDR2 of a monoclonal antibody: Binding analysis and factors that influence the isomerization rate.
    Dick LW; Qiu D; Wong RB; Cheng KC
    Biotechnol Bioeng; 2010 Feb; 105(3):515-23. PubMed ID: 19806678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cross-reactive binding of cyclic peptides to an anti-TGFalpha antibody Fab fragment: an X-ray structural and thermodynamic analysis.
    Hahn M; Winkler D; Welfle K; Misselwitz R; Welfle H; Wessner H; Zahn G; Scholz C; Seifert M; Harkins R; Schneider-Mergener J; Höhne W
    J Mol Biol; 2001 Nov; 314(2):293-309. PubMed ID: 11718562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phage-displayed antibody libraries of synthetic heavy chain complementarity determining regions.
    Sidhu SS; Li B; Chen Y; Fellouse FA; Eigenbrot C; Fuh G
    J Mol Biol; 2004 Apr; 338(2):299-310. PubMed ID: 15066433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiplexed monitoring of therapeutic antibodies for inflammatory diseases using Fab-selective proteolysis nSMOL coupled with LC-MS.
    Iwamoto N; Takanashi M; Yokoyama K; Yonezawa A; Denda M; Hashimoto M; Tanaka M; Ito H; Matsuura M; Yamamoto S; Honzawa Y; Matsubara K; Shimada T
    J Immunol Methods; 2019 Sep; 472():44-54. PubMed ID: 31201793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The crystal structure of the pathogenic collagen type II-specific mouse monoclonal antibody CIIC1 Fab: structure to function analysis.
    Uysal H; Sehnert B; Nandakumar KS; Böiers U; Burkhardt H; Holmdahl R; Thunnissen MM
    Mol Immunol; 2008 Apr; 45(8):2196-204. PubMed ID: 18241923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular characterization of monoclonal antibodies against aflatoxins: a possible explanation for the highest sensitivity.
    Li X; Li P; Zhang Q; Li Y; Zhang W; Ding X
    Anal Chem; 2012 Jun; 84(12):5229-35. PubMed ID: 22548609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cloning and characterization of a single-chain fragment of monoclonal antibody to ACE suitable for lung endothelial targeting.
    Balyasnikova IV; Berestetskaya JV; Visintine DJ; Nesterovitch AB; Adamian L; Danilov SM
    Microvasc Res; 2010 Dec; 80(3):355-64. PubMed ID: 20888351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of humanized anti-DNA hydrolyzing catalytic antibodies by complementarity determining region grafting.
    Kim DS; Lee SH; Kim JS; Lee SC; Kwon MH; Kim YS
    Biochem Biophys Res Commun; 2009 Feb; 379(2):314-8. PubMed ID: 19103171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Three-dimensional structure of an anti-steroid Fab' and progesterone-Fab' complex.
    Arevalo JH; Stura EA; Taussig MJ; Wilson IA
    J Mol Biol; 1993 May; 231(1):103-18. PubMed ID: 8496956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.